Axiom Biotechnologies Continues to Spotlight Drug Discovery in Additions to Scientific Advisory Board.Business Editors & Health/Medical Writers BIOWIRE2K SAN DIEGO--(BW HealthWire)--April 10, 2001 New Members Paul England Paul England (born in Melbourne, March 28, 1929) is an Australian former racing driver. He worked for the Repco company and raced his own Holden-powered Ausca sports racing car that used a fibreglass body based on the A6GCS Maserati. , Ph.D., Paul Insel, M.D., Curtis Klaassen, Ph.D., and David Webb David Webb can refer to:
to Axiom's Scientific Advisory Board Axiom Biotechnologies Inc. announced the addition of Paul England, Ph.D., Paul A. Insel M.D., Curtis D. Klaassen, Ph.D., and David R. Webb, Ph.D., to its Scientific Advisory Board. Paul England was the Senior VP of Research at Aurora Biosciences and is at present the Senior Scientific Fellow and had a key role in the development and implementation of Aurora's UHTS UHTS Ultrahigh-Throughput Screening (Pharmaceutical Industry) UHTS Universal Hydraulic Test Stand screening platform. Dr. England had previously served as VP Cellular Biochemistry and VP Molecular Screening Technologies at SmithKline Beecham. Paul Insel is Professor of Pharmacology and Professor of Medicine at the University of California, San Diego UCSD is consistently ranked among the top ten public universities for undergraduate education in the United States by U.S. News & World Report.[3] It is a Public Ivy. [1] For graduate studies, most of UCSD's Ph.D. , and Director of the Medical Scientist Training Program. Dr. Insel is a recognized expert in the field of receptors, particularly G-protein coupled receptors (GPCRs), and in the identification of small molecule drug candidates that interact with them. Curtis Klaassen, Professor of Pharmacology and Toxicology at the University of Kansas The University of Kansas (often referred to as KU or just Kansas) is an institution of higher learning in Lawrence, Kansas. The main campus resides atop Mount Oread. Medical Center, is an international expert in the field of pharmacology and toxicology. Dr. Klaassen has served as Chairman of Scientific Counselors for the National Toxicology Program National Toxicology Program Environment A program that conducts toxicologic tests on substances frequently found at the EPA's National Priorities List sites, which have the greatest potential for human exposure and is a member of the Academy of Toxicology Sciences. David Webb serves as Corporate VP, Technology, at OSI Pharmaceuticals OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. They specialize in the discovery and development of molecular targeted therapies, and are listed in the NASDAQ . Dr. Webb has significant experience in drug discovery having previously served as VP of Research and Chief Scientific Officer at Cadus Pharmaceuticals and Distinguished Scientist and Director of the Institute of Immunology and Biological Sciences at Syntex (now Roche Biosciences). Dr. Webb is a recognized leader in the area of identifying drug candidates in the areas of Inflammation, Transplantation and Allergic Diseases. "Paul England's experience in high-throughput screening and Curtis Klaassen's extensive knowledge of pharmacology and toxicology will be of significant value as we continue to expand our compound screening and lead evaluation capabilities," stated Dr. Pandi Veerapandian, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Axiom. "In addition, the GPCR GPCR Guanine Nucleotide-Binding Protein-Coupled Receptor GPCR GTP-binding Protein-Coupled Receptor expertise of David Webb and Paul Insel will be a major asset to both our collaborative and our internal drug discovery programs since GPCRs represent one of the most important classes of drug discovery targets." Axiom Biotechnologies is a privately-held biotechnology company focused on the more rapid production of drugs that are more effective and safer, through the application of its proprietary suite of high-definition cell based drug discovery technologies. These include the Axiom Human Cell Bank, a large pharmacologically and genomically characterized collection of human cells, as well as instrumentation and other technologies for rapidly discovering better drugs. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion